Meeting NewsVideo

BTK inhibitors provide ‘exciting time’ for the treatment of lymphoma subtype

ATLANTA — Three studies evaluating the use of different Bruton’s tyrosine kinase inhibitors presented at the ASH Annual Meeting and Exposition demonstrated ‘particularly impressive’ results and have the potential to add to the armamentarium to treat mantle cell lymphoma, according to Jonathon B. Cohen, MD, MS, medical director of infusion services at Winship Cancer Institute of Emory University.

Cohen, who co-moderated the session that included the three studies, spoke with HemOnc Today about how the results from Rule and colleagues, Tam and colleagues, and Wang and colleagues demonstrate benefits with BTK inhibitors in patients with mantle cell lymphoma.

“As we start to interpret the results of these studies ... one of the big questions is how these agents should be sequenced in therapy and what should be used under which circumstances,” Cohen said. “One of the challenges that we have seen with ibrutinib [Imbruvica; Janssen, Pharmacyclics] is that although it is very effective, there have been some unique toxicities including atrial fibrillation, hypertension and bleeding. It appears that some of these newer therapies including acalabrutinib [Calquence, AstraZeneca] may not have some of these toxicities. BGB-3111 [BeiGene] is still a little bit earlier on in its development, but also appears to have a very favorable toxicity profile and while it's currently only available as an investigational agent, I think it will provide an excellent opportunity for physicians to consider in the future.”

Reference:

Rule S, et al. Abstract 151. Presented at: ASH Annual Meeting and Exposition; Dec. 9-12, 2017; Atlanta.

Tam CS, et al. Abstract 152. Presented at: ASH Annual Meeting and Exposition; Dec. 9-12, 2017; Atlanta.

Wang M, et al. Abstract 155. Presented at: ASH Annual Meeting and Exposition; Dec. 9-12, 2017; Atlanta.

Disclosures: Cohen reports no relevant financial disclosures.

ATLANTA — Three studies evaluating the use of different Bruton’s tyrosine kinase inhibitors presented at the ASH Annual Meeting and Exposition demonstrated ‘particularly impressive’ results and have the potential to add to the armamentarium to treat mantle cell lymphoma, according to Jonathon B. Cohen, MD, MS, medical director of infusion services at Winship Cancer Institute of Emory University.

Cohen, who co-moderated the session that included the three studies, spoke with HemOnc Today about how the results from Rule and colleagues, Tam and colleagues, and Wang and colleagues demonstrate benefits with BTK inhibitors in patients with mantle cell lymphoma.

“As we start to interpret the results of these studies ... one of the big questions is how these agents should be sequenced in therapy and what should be used under which circumstances,” Cohen said. “One of the challenges that we have seen with ibrutinib [Imbruvica; Janssen, Pharmacyclics] is that although it is very effective, there have been some unique toxicities including atrial fibrillation, hypertension and bleeding. It appears that some of these newer therapies including acalabrutinib [Calquence, AstraZeneca] may not have some of these toxicities. BGB-3111 [BeiGene] is still a little bit earlier on in its development, but also appears to have a very favorable toxicity profile and while it's currently only available as an investigational agent, I think it will provide an excellent opportunity for physicians to consider in the future.”

Reference:

Rule S, et al. Abstract 151. Presented at: ASH Annual Meeting and Exposition; Dec. 9-12, 2017; Atlanta.

Tam CS, et al. Abstract 152. Presented at: ASH Annual Meeting and Exposition; Dec. 9-12, 2017; Atlanta.

Wang M, et al. Abstract 155. Presented at: ASH Annual Meeting and Exposition; Dec. 9-12, 2017; Atlanta.

Disclosures: Cohen reports no relevant financial disclosures.

    See more from Discoveries from ASH Non-Hodgkin Lymphoma